Neuphoria Therapeutics Inc 6-K, filed Nov 28, 2023
Neuphoria Therapeutics Inc. (NEUP)
About this 6-K
Neuphoria Therapeutics Inc filed this 6-K on November 28, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2023
(Commission File No. 001-41157)
BIONOMICS LIMITED
(Translation of registrant’s name into English)
200 Greenhill Road
Eastwood SA 5063
Tel: +618 8150 7400
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ☐ No ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ☐ No ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On November 28, 2023, the Company gave notice to shareholders as required by the laws and regulations of Australia that Dr Errol De Souza will not be standing for re-election to the Company’s Board of Directors at the upcoming Annual General Meeting (“AGM”) on November 30, 2023. The announcement is furnished herewith as Exhibit 99.1 to this report on Form 6-K.
1
EXHIBIT INDEX
|
|
Exhibit
|
Description
|
99.1 |
|
|
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
Bionomics Limited |
|
|
(Registrant) |
|
|
|
|
|
By: |
/s/ Alan Fisher
|
|
Name: |
Alan Fisher |
|
Title: |
Chairman |
Date: November 28, 2023
1
Exhibit 99.1
Bionomics Announces Retirement of Board Member
ADELAIDE, Australia, and CAMBRIDGE, Mass., November 28, 2023 -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr. Errol De Souza will not be standing for re-election to the Company’s Board of Directors at the upcoming Annual General Meeting (“AGM”) on November 30, 2023, which retirement from the Board will be effective as of the AGM. Following Dr. De Souza’s retirement from the Board of Directors, it will be now composed of a total of 6 Directors.
“On behalf of the Board and the Bionomics team I would like to thank Dr. De Souza for his leadership and contributions to Bionomics, both as a Non-Executive Director as well as Executive Chair and wish him all the best in the future” commented Alan Fisher, Non-Executive Chair of the Board of Directors of Bionomics.
“Errol has been a valuable long-standing member of the Board for over 15 years”, added Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “We truly appreciate his service, insights and support throughout the years and wish him all the best in his future endeavours.”
The Company plans to advance its lead asset, BNC210, to Phase 3 study in social anxiety disorder, and following the positive Phase 2 results in post-traumatic stress disorder is preparing for an End of Phase 2 meeting with the U.S. Food & Drug Administration.
FOR FURTHER INFORMATION PLEASE CONTACT:
General Rajeev Chandra Company Secretary CoSec@bionomics.com.au |
Investor Relations Kevin Gardner kgardner@lifesciadvisors.com
|
Investor Relations Chris Calabrese |
|
|
|
About Bionomics Limited
Bionomics (NASDAQ:BNOX) is a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au